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1. Introduction 
Breast cancer is the most common type of malignancy in the world and is also one of the 
major reasons of mortality among women worldwide. It exhibits a vast variety of 
pathological features and clinical signs and said to be a heterogeneous disease (Jemal et al., 
2009). It is also among the most studied cancers, but the biology of it is still not well 
understood (Fang et al., 2011). Genetics, inheritance, aging are major risk factors for breast 
cancer, while hormonal factors, obesity (imitating in diet and exercise), and alcohol use 
presenting more diffident risk. Breast cancer mortality has been found to be decreasing 
gradually since 1990s, after the improvement of breast cancer screening techniques and the 
advancement of treatment approaches (Jatoi and Miller, 2003; and Tabar et al., 2003).  
1.1 Incidence of breast cancer in Pakistan 
In Pakistan, breast cancer has maximum prevalence of all types of cancer, with frequencies 
similar to Western population. It affects mostly young women (45 or above) in Pakistan with 
a high frequency as compared to Caucasian women (Kakarala et al., 2010), often presenting 
in advanced stage (Malik, 2002). The low socio-economic status and reproductive issues 
such as low parity and late first pregnancy may be responsible for higher incidence of breast 
cancer in Pakistan. It is described that patients with lower socio-economic status (SES) had 
larger, more aggressive tumors with worsened survival outcomes (Aziz et al., 2010). The 
mutations of BRCA1 and BRCA2 genes are also considered as responsible factors for the 
greater numbers of breast cancer in Pakistan. As Pakistan has the maximum number of 
consanguineous marriages in the world (Hashmi, 1997), the transfer of these mutations after 
such marriages is supposed to be a vital factor in raising breast cancer cases in Pakistan 
(Shami et al., 1991). The inheritance of recessive genes has been reported to increase the 
breast cancer risk in Pakistan (Liede et al., 2002). But the exact reasons for high incidence of 
breast cancer in Pakistan are still to be detected.  
All these risks put an emphasis on the development of better treatment strategies for breast 
cancer. Early finding of diseased condition, improvements in scientific methodologies and 
quality of care, with sufficient economic guidelines, need to be developed for countries with 
limited resources like Pakistan (Aziz et al., 2008). 
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2. Biological explanation of breast cancer 
Breast cancer usually arises after menopause (age: 40+), but it can also arise before 
menopause in very rare cases. The ovarian-pituitary axis synchronizes the normal breast 
physiology during the reproductive cycle. The biological reason for it is that the glandular 
component of the breast gradually degenerates after menopause and the breast is mostly 
substituted by adipose tissue. Any problem in this process causes the development of breast 
cancer, whereas by epithelial cells of the breast ducts, uncontrolled growth and survival 
takes place, and in later stages the characteristics of neo-angiogenesis, invasion and 
metastasis occurs (Heldermon and Ellis, 2006). 
3. Treatment and prevention 
Breast cancer prevention is primarily made by pharmacoprevention using fenretinide and 
tamoxifen. The regular use of screening techniques for early detection of breast cancer is the 
best strategy to decrease death rates (Veronesi and Boyle, 1993). Better treatments include 
targeted chemotherapy, endocrine therapy, radiotherapy and surgery, inhibitors of certain 
proteins and more recently immune therapy (monoclonal antibodies) and miRNA therapy. 
Advancement in life style may also be a good treatment for breast cancer. Breast cancer 
threat may be reduced by physical activities or exercise (Eliassen et al., 2010). 
Many targeted genetic and molecular agents have been developed for efficient treatment of 
breast cancer, by keeping in view certain biomolecular characteristics of breast cancer, such 
as mutations of breast cancer susceptibility gene type 1, 2 (BRCA1/BRCA2) (Chen and 
Parmigiani, 2007), abnormal activation of human epidermal growth factor receptors (EFGR) 
(Wang and greene, 2007), overexpression of human epidermal growth factor receptor-2 
(HER-2) (Ross et al., 2003), and activation of vascular endothelial growth factor (VEGF) 
receptor (Bhinder and Ramaswamy, 2010). It is reported that more than half of the breast 
cancer cases are due to errors in hormone receptor proteins. For this reason, the primary 
concern of today’s research is endocrine therapy. The development of targeting molecular 
agents is also among major goals of current research for efficient treatment of advanced 
breast cancer. 
The major obstacles in treatment of breast cancer are resistance to therapeutic agents 
(Serrano-Olvera et al., 2006). Women with breast cancer treatment and surgery have 
complaints of tension and depression. By using different treatment strategies including 
mastectomy, adjuvant chemotherapy, many women have shown incidence of nervousness 
and depression associated with cancer that puts unpleasant effects on the life status and 
emotional working. 
3.1 Chemotherapy 
Chemotherapy is the most primitive method for treating breast cancer, if employed 
immediately after surgery, termed as adjuvant chemotherapy (AC), and administered before 
surgery, neoadjuvant chemotherapy (NAC) (Alvarado-Cabrero et al., 2009). Chemotherapy 
is recommended for all women with invasive cancer greater than 1 centimeter (Ganz et al., 
2011). Adjuvant chemotherapy is associated with significantly more severe physical 
symptoms, including musculo-skeletal pain, vaginal and weight problems and nausea 
(Ganz et al., 2011). 
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3.1.1 Neoadjuvant chemotherapy 
Neoadjuvant chemotherapy (NAC) has been a common approach for the management and 
treatment of locally advanced breast cancer (LABC). It is applied very effectively for 
treatment of patients with LABC before breast and axillary lymph node resection (Pusztai, 
2008). The NAC is aimed to reduce tumor size subsequently aiding mastectomy and 
radiotherapy (Cleator et al., 2002; and Pusztai, 2008). NAC is better treatment option because 
it averts adverse physiological reactions (Alvarado-Cabrero et al., 2009). 
Patients of LABC had showed complete clinical and pathological response to NAC, while 
those with pure micropapillary carcinoma (PMC) gave incomplete response (Alvarado-
Cabrero et al., 2009). Patient’s therapy effect can be predicted by clinical & pathological 
responses (Jones et al., 2006), and by biomarker levels in the patients, which have better 
prognostic influence in contrast to pathological and clinical response, multi-biomarker levels 
have showed better expressive power for treatment outcome as compared with single 
biomarker level (Nolen et al., 2008).  
Paclitaxel is a chemical agent applied before radiotherapy and surgery. It binds to tubulin 
resulting in cell cycle arrest at M-phase which enhances radiation sensitivity. In a report, 
Patients having 3 cycles of paclitaxel followed by simultaneous radiotherapy before specific 
surgery, showed better results as compared those without paclitaxel (Chakravarthy et al., 
2000). The most common approach for treating LABC in developed countries consists of 
NAC with anthracyclines and taxanes followed by surgery and radiation therapy (Osako et 
al., 2007). HR-positive tumors are less chemosensitive so an anthracyline based NAC is 
developed without hormonal treatment to evaluate estrogen receptor (ER) and progesterone 
receptor (PgR) semi-quantitative expression in patients with HR-positive tumors (Petit et al., 
2010). Preoperative and postoperative marker studies in NAC might facilitate tumor 
analysis and to observe possible change in status respectively (Piper et al., 2004). 
3.2 Endocrine therapy 
An understanding of the mechanism of action, pharmacology and clinical indications for 
various classes of endocrine agent is critical for the management of breast cancer 
(Heldermon and Ellis, 2006). Breast cancer is divided into three major molecular types 
which are diagnosed by routine histopathological tests: (i) hormone receptor-positive 
(ER/PR+), (ii) human epidermal growth factor receptor type 2 enriched (HER2+) and (iii) 
triple negative (ER-, PR-, HER2-) breast cancer (TNBC). HR+ breast cancers comprise about 
60–70% of all the clinically positive breast cancers, while the other two types equally 
accounts for the remaining 30–40% of all breast cancer cases (Slamon et al., 1989). Endocrine 
therapy has been used before surgery but Dittmer et al., (2011) reported adjuvant endocrine 
therapy not so effective for breast tumor treatment because of its side effects (Dittmer et al., 
2011).  
3.2.1 HER2+ breast cancer and targeted therapy 
The HER2 overexpression due to gene amplification or transcriptional deregulation (Slamon 
et al., 1989) presents a poorer prognosis, with development of resistance to many 
chemotherapeutic and hormonal agents, and a rise in tendency of metastasis to brain 
(Serrano-Olvera et al., 2006).  
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3.2.2 Monoclonal antibodies for endocrine therapy 
The basic purpose of current therapeutic policies is to make overexpressed HER2 silent 
with certain targeted complexes e.g., trastuzumab, a monoclonal antibody prepared for 
humans against HER2 protein, reported to be a well accepted therapy for women with 
MBC (Vogel et al., 2002). This antibody specifically hinders the HER2-mediated activation 
of intracellular kinases and other molecules (Valabrega et al., 2007). The combination of 
chemotherapy and trastuzumab extends the life of patient in adjuvant and metastatic 
patterns, but most women with HER2+ metastatic tumor become resistant to trastuzumab; 
about 15–25% of women detected with early HER2+ disease have trastuzumab-resistant 
tumors (Bedard et al., 2009).  
The combinations of anti-HER2 agents should close to abolish acquired drug resistance, 
shorten the period of therapy, and potentially dole out with the need of coexisting 
chemotherapy, because the anti-HER2 therapies including drugs trastuzumab and lapatinib, 
targeted against the HER2 signaling network has gradually changed the natural history  
of early and metastatic HER2-overexpressing breast cancer (Abramason and Artega,  
2011). 
3.2.3 HR+ breast cancer and targeted therapy 
Estrogen is a well-characterized growth factor in about 60–70% of breast cancer patients 
(Clemons and Goss, 2001). The malignant epithelial cells depend on reproductive hormones, 
specifically estrogen in ER+ tumors (Heldermon and Ellis, 2006). The initial endocrine 
therapy of breast cancer was removal of the ovaries (oophorectomy) (Taylor et al., 1998). 
Many thriving remedies have been formulated to decrease or eradicate circulating estrogen 
or to obstruct its communication with genomic target objects. The specific ER antagonist 
tamoxifen is recommended as adjuvant endocrine therapy for the hormone receptor positive 
early breast cancer (Sehdev et al., 2009).  Endocrine therapies for ER+ patients include three 
types of agents that (i) directly target ER through molecules that bind ER and change ER 
function; (ii) estrogen deprivation through aromatase inhibition or ovarian suppression; and 
(iii) sex steroid therapies, including estrogen, progestins and androgens. 
3.2.4 Selective Estrogen Receptor Modulators (SERM) 
The rise of estrogen level in blood proposed the use of a therapeutic modulator to oestrogen, 
a selective oestrogen receptor modulator, or SERM (Jordan, 1999). The evidences from 
breast cancer treatment trials presented the ability of the first SERM, tamoxifen, to avoid 
tumors in the contralateral breast of women receiving adjuvant therapy (Ragaz and 
Coldman, 1998). Tamoxifen considerably lessens the rate of treatment failure in breast 
cancer patients, with lesser frequency of clinically obvious toxic effects. For tamoxifen, 
response rates range from 16 to 56%, and an improved toxicity profile than alternative 
therapies, for example large dosage of estrogen or adrenalectomy results in quick 
acceptance of tamoxifen as a selective cure for advanced disease (Muss et al., 1994). The 
combination of ovarian suppression and tamoxifen is referred to as the first line therapy for 
HR+ advanced breast cancer in pre-menopausal women. Some examples of SERM comprise 
raloxifene and toremifine (Holli et al., 2000; and Martino et al., 2004).  
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3.2.5 Tyrosine kinase inhibitors 
Lapatinib is an oral, selective, reversible small-molecule dual tyrosine kinase inhibitor of both 
the ErbB1 and ErbB2 signaling pathway that works by inhibiting growth and guiding to cell 
arrest and apoptosis. It is presented to be effective against HER-2+, LABC and metastatic breast 
cancer (MBC). The primary activity of lapatinib in breast cancer patients is mediated through 
HER-2 inhibition. In addition, lapatinib treatment inhibits the growth of ErbB2-overexpressing 
human breast cancer cells that showed resistance to trastuzumab. Clinically related antitumor 
activity has not been reported when lapatinib is used in the mixed population of LABC patients 
with distinct HER-2 negative or HER-2 untested tumors (Leo et al., 2008). Patients with HER-2 
negative or HER-2 untested MBC had not showed any advantage from lapatinib therapy. 
However, the first-line therapy with paclitaxel and lapatinib in combination expressed 
improved clinical outcomes in HER-2+ patients. Future assessment of the effectiveness and 
safety of this combination is constant in early and metastatic HER-2+ breast cancer patients. A 
combined targeted approach with letrozole and lapatinib has appreciably improved 
progression free survival in patients with MBC that coexpresses HR and HER2. 
3.2.6 Triple-negative breast cancer treatment 
CCN1, also known as Cyr61 (cysteine-rich 61), is a proangiogenic factor, increased CCN1 
expression is associated with the development of tumors (O'Kelly et al., 2008), e.g., in about 
30% of invasive breast carcinomas, and particularly in triple-negative breast carcinomas 
(TNBC). TNBCs patients had been treated with bisphosphonate in combination to 
chemotherapy. Zoledronic acid (ZOL) is a bisphosphonate having direct antitumor activity 
in breast tumor cells by preventing independent growth, branching and morphogenesis by 
targeting CCN1 overexpressing cells through a negative regulation of CCN1 by FOXO3a; it 
is a new therapeutic approach for TNBC (Espinoza et al., 2011). 
3.3 Anti-angiogenic therapies 
Angiogenesis is the mandatory step in tumor development, so anti-angiogenic agents can be 
developed for the better management and prevention of breast tumor. The monoclonal 
antibody to platelet/endothelial cell adhesion molecule (PECAM) has proved to be a 
sensitive and specific marker for endothelial cells; these antibodies might reduce the tumor 
size or hinder the development of metastatic tumors (Horak et al., 1992). 
3.3.1 Viral vector therapy 
Expression of VEGF in several types of tumors is amplified, subsequently correlated with 
weak prognosis of several tumors. Im et al (2001) used transfection method to create a 
replication-deficient adenoviral vector containing antisense VEGF cDNA (Ad5CMV-
αVEGF) to down-regulate VEGF expression. This therapeutic strategy notably repressed the 
growth of developed breast tumors (Im et al., 2001). These viral vectors may be used in 
future for targeting the tumor vasculature in breast cancer therapy. 
3.4 Surgery 
Mastectomy is total removal of one or both breasts; it is frequently used in treatment of 
invasive breast cancers in early stages (Veronesi et al., 2002). Bilateral mastectomy is 
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effective therapeutic approach for breast cancers with BRCA1 and BRCA2 mutations 
(Meijers-Heijboer et al., 2001). Lumpectomy or breast conserving surgery (i.e., surgical 
removal of discrete tumor from breast) may be used alone or in combination with 
subsequent radiotherapy, later is reported to be more appropriate therapy for invasive 
breast cancer; because the risk of ipsilateral recurrence of breast cancer is very low in 
lumpectomy with irradiation as compared with mastectomy and lumpectomy alone (Fisher 
et al., 2002). For hormone receptor positive breast cancer, initial treatment option was 
surgical removal of ovaries, oophorectomy (Taylor et al., 1998). 
3.5 Radiotherapy 
Radiotherapy is applied after surgery, i.e., adjuvant radiotherapy. Cardiovascular disease 
continues to be chief problem of radiotherapy in breast cancer patients, but a little is known 
about it yet; It raises the enduring threat for cardiovascular mortality, predominantly in 
women treated for left-sided breast cancer; the mortality rate due to cardiac disease may boost 
to double in left-sided breast cancer survivors as compared to right-sided breast cancer 
patients (Foody, 2011). In women (aged 70+) with tumors larger than 5 cm, minor local 
regional recurrence (LRR)  was observed through radiotherapy following mastectomy than 
those lacking radiotherapy (Truong et al., 2005); Post-mastectomy radiotherapy (PMRT) might 
be helpful in the managing breast cancer with high-risk features (Lee et al., 2005). Adjuvant 
radiotherapy is proved to be a breast conserving therapy (BCT) in younger women, it is not 
frequently recommended for patients with older age (Nagel et al., 2002). Postoperative 
radiotherapy is normally in use for treating patients with positive surgical margins following 
mastectomy but a little data is present to sustain this approach (Truong et al., 2004). 
3.6 miRNA therapy 
Each tumor type seems to have a unique miRNA marker, and such markers are being 
oppressed to recognize the tissue of origin of metastatic tumors and to distinguish between 
different cancer subtypes (Lu et al., 2005). Furthermore, miRNA expression markers are 
linked to numerous clinicopathological features for instance tumor stage, receptor status 
and patient survival. Eventually, it is likely to make profiles that characterize a probable link 
between circulating miRNAs, disease status, basic subtype and HER2+ status, therapeutic 
response and metastatic risk. As miRNA expression is vanished during MBC, the renovation 
of these miRNAs’ expression may suppress MBC; for example, miR-126 renovation reported 
to decrease in general tumor growth and propagation, and miR-335 presented to inhibit 
metastatic cell invasion (Tavazoie et al., 2008). 
3.7 Male breast cancer and treatment 
Breast cancer is recently described to exist in males too. Tamoxifen, aromatase inhibitors and 
GnRH analogues targeting on HER2-directed therapies, PARP inhibitors, and angiogenesis 
inhibitors are reported endocrine therapeutic strategies for treating male breast cancer 
(Onami et al., 2010). 
4. Conclusion 
Breast cancer is a heterogeneous disease and has become the most common cancer in 
women throughout the world. Known risk factors include age, dietary features, 
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reproductive hormonal imbalance, genetic predispositions, alcoholism, and breast adipose 
tissue density. Breast cancer is major cause of mortality of women worldwide. Keeping in 
view the above discussion, here is a need of developing better therapeutic plans for 
hampering breast cancer risks and reducing mortality due to breast cancer. Research 
investigating cultural, environmental, and genetic issues of breast cancer should be taken 
into consideration for development of better treatment plans and to present additional 
details for the clinical and pathological features. The molecular, endocrine and genetic 
means should be the major goals of today’s efforts for treatment of breast cancer. 
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